39.70
-0.615(-1.53%)
Currency In USD
| Previous Close | 40.31 |
| Open | 40.19 |
| Day High | 40.19 |
| Day Low | 39.46 |
| 52-Week High | 62.58 |
| 52-Week Low | 23.42 |
| Volume | 45,836 |
| Average Volume | 636,523 |
| Market Cap | 2.31B |
| PE | -5.66 |
| EPS | -7.01 |
| Moving Average 50 Days | 39.72 |
| Moving Average 200 Days | 34.82 |
| Change | -0.62 |
If you invested $1000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, it would be worth $610.32 as of November 07, 2025 at a share price of $39.695. Whereas If you bought $1000 worth of Agios Pharmaceuticals, Inc. (AGIO) shares 5 years ago, it would be worth $976.51 as of November 07, 2025 at a share price of $39.695.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Nov 03, 2025 2:01 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data o
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
GlobeNewswire Inc.
Oct 17, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Commit
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
GlobeNewswire Inc.
Oct 16, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company wil